Achievement reframed as down-payment: management treats what was just accomplished mainly as the unlock for a bigger, na
The model's full reasoning — Q1 2024 call → NOWe need to determine if management treats a real recent accomplishment as the key that unlocks a bigger, identified next stage. The call has several accomplishments: NanoKnife PRESERVE study enrollment completed, Auryon growth, AngioVac breakthrough designation, APEX PE study enrollment 75%, etc. The question asks if management takes something real and treats it primarily as the key that unlocks a bigger, identified next stage, spending more energy on what the accomplishment makes possible than on celebrating the accomplishment itself. Look for a specific accomplishment that is framed as enabling a larger stage. For example, the PRESERVE study completion: management says they enrolled final patient, will collect data, submit to FDA, and then expand indication for NanoKnife to treat prostate tissue. They talk about the market potential ($700M US, $2B global). They say "We believe that the timing of our submission is ideal... interest and desire for focal therapy continues to build... We believe that NanoKnife will be the best option for this patient population." They are looking forward to providing details as physicians publish data. This seems like they are treating the completion of enrollment as a milestone that enables the next stage: getting FDA approval and expanding the market. But is that a "larger, identified stage" that is already in motion? They have the study done, they will submit data, but the approval is not yet obtained. The next stage depends on FDA approval, which is a decision not yet made. The question says: "NO if the next stage depends chiefly on approvals, financing, market recovery, or decisions not yet made." So that would be a NO for that. Another accomplishment: AngioVac breakthrough designation. They received breakthrough designation for right heart vegetation. They are engaging with FDA to finalize study design. That is also dependent on approvals. Auryon: they are planning to launch catheters for small vessel DVT in 2025, and pursuing CAD indication. That is future. What about the overall Med Tech growth? They report strong growth, but that is just reporting.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| DXLG | Destination XL Group, Inc. | Q2 2023 | 2023-08-24 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
MNKD · Q4 2023 → YESThe question is: Does management take something REAL the company just accomplished and treat it primarily as the KEY THAT UNLOCKS A BIGGER, IDENTIFIED NEXT STAGE — spending more of its energy on what ...YES The transcript shows management framing the recent royalty sale (announced early January, closed in the reported period) and resulting $302 million cash position as the concrete enabler that now allows them to fund the identified next stage—advancing MNKD-101 into Phase 3 and MNKD-201 into Phase 1— without needing further commercial monetization or dilution.
HCKT · Q1 2024 → YESThe question is: Does management take something REAL the company just accomplished and treat it primarily as the KEY THAT UNLOCKS A BIGGER, IDENTIFIED NEXT STAGE — spending more of its energy on what ...
LTRX · Q3 2024 → YESThe question is: Does management take something REAL the company just accomplished and treat it primarily as the KEY THAT UNLOCKS A BIGGER, IDENTIFIED NEXT STAGE — spending more of its energy on what ...